CStone Pharmaceuticals (2616.HK)
2616.HK Stock Price Chart
Explore CStone Pharmaceuticals interactive price chart. Choose custom timeframes to analyze 2616.HK price movements and trends.
2616.HK Company Profile
Discover essential business fundamentals and corporate details for CStone Pharmaceuticals (2616.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Feb 2019
Employees
135.00
Website
https://www.cstonepharma.comCEO
Jianxin Yang
Description
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
2616.HK Financial Timeline
Browse a chronological timeline of CStone Pharmaceuticals corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Mar 2026
Earnings released on 14 Aug 2025
EPS came in at -$0.23 falling short of the estimated -$0.11 by -110.00%, while revenue for the quarter reached $54.19M , missing expectations by -54.15%.
Earnings released on 18 Jun 2025
Earnings released on 26 Mar 2025
EPS came in at -$0.05 falling short of the estimated -$0.03 by -45.07%, while revenue for the quarter reached $84.67M , missing expectations by -74.71%.
Earnings released on 31 Dec 2024
EPS came in at -$0.04 , while revenue for the quarter reached $81.40M .
Earnings released on 23 Aug 2024
EPS came in at $0.01 surpassing the estimated -$0.11 by +106.15%, while revenue for the quarter reached $136.47M , missing expectations by -58.88%.
Earnings released on 18 Jun 2024
EPS came in at $0.01 , while revenue for the quarter reached $137.49M .
Earnings released on 28 Mar 2024
EPS came in at -$0.07 surpassing the estimated -$0.11 by +37.62%, while revenue for the quarter reached $111.99M , missing expectations by -84.66%.
Earnings released on 17 Jan 2024
EPS came in at -$0.07 , while revenue for the quarter reached $108.53M .
Earnings released on 25 Aug 2023
EPS came in at -$0.09 , while revenue for the quarter reached $141.38M , missing expectations by -82.76%.
Earnings released on 16 Aug 2023
EPS came in at -$0.10 surpassing the estimated -$0.31 by +69.56%, while revenue for the quarter reached $149.23M , missing expectations by -61.19%.
Earnings released on 16 Mar 2023
EPS came in at -$0.25 surpassing the estimated -$0.46 by +45.24%, while revenue for the quarter reached $120.62M , missing expectations by -86.17%.
Earnings released on 31 Dec 2022
EPS came in at -$0.26 , while revenue for the quarter reached $125.05M .
Earnings released on 25 Aug 2022
EPS came in at -$0.18 surpassing the estimated -$0.48 by +62.54%, while revenue for the quarter reached $153.22M , missing expectations by -25.91%.
Earnings released on 1 Jun 2022
EPS came in at -$0.60 surpassing the estimated -$0.85 by +29.52%, while revenue for the quarter reached $100.56M , missing expectations by -56.34%.
Earnings released on 31 Mar 2022
EPS came in at -$0.19 , while revenue for the quarter reached $161.30M .
Earnings released on 30 Sept 2021
EPS came in at -$0.59 , while revenue for the quarter reached $99.07M .
Earnings released on 26 Aug 2021
EPS came in at -$0.40 surpassing the estimated -$0.99 by +59.74%, while revenue for the quarter reached $47.04M .
Earnings released on 30 Jun 2021
EPS came in at -$0.40 , while revenue for the quarter reached $47.69M .
Earnings released on 26 Mar 2021
EPS came in at -$0.29 surpassing the estimated -$1.10 by +73.67%, while revenue for the quarter reached $592.25M , beating expectations by +54.55K%.
Earnings released on 31 Dec 2020
EPS came in at -$0.30 , while revenue for the quarter reached $616.87M .
2616.HK Stock Performance
Access detailed 2616.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.